A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Recruiting · Phase 1, Phase 2 · NCT05372354
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $402,716
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 260
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- CC-92480 (drug), Tazemetostat (drug), BMS-986158 (drug), Trametinib (drug), Dexamethasone (drug)
- Dates
- Started 2022-10-18; completion 2026-10-12
- Results posted
- Not yet
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
From ClinicalTrials.gov, last updated 2025-09-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $402,716 in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Syed Abbas Ali, MD Medical Oncology · Jasper, AL
- Luciano Costa Hematology & Oncology · Birmingham, AL
- Clifton C. Mo, M.D. Medical Oncology · Boston, MA
- David S. Siegel, MD Medical Oncology · Hackensack, NJ
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Uab Comprehensive Cancer Center $277,548
- John Theurer Cancer Center $48,979
- Dana-Farber Cancer Institute $43,537
- Johns Hopkins Medicine - the Sidney Kimmel Comprehensive Cancer Center $32,653
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.